IPM Take
This is not just a China approval. It is a signal that oncology innovation is becoming more multipolar. ESCC is a high-burden disease in China, and patients progressing after platinum chemotherapy and checkpoint inhibition have limited options. The access challenge now is whether a survival-improving ADC can move beyond approval into broad, affordable, real-world delivery.
Executive Summary
SystImmune announced that China’s National Medical Products Administration approved iza-bren, or izalontamab brengitecan, for adults with recurrent or metastatic esophageal squamous cell carcinoma after progression on platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy. The approval is supported by the Phase III PANKU-Esophagus01 trial, which randomized 497 patients across 80 study centres in China. Iza-bren improved median overall survival to 9.8 months versus 7.2 months with chemotherapy and improved median progression-free survival to 4.2 months versus 2.0 months. Treatment discontinuation due to treatment-related adverse events was reported at 2.0%.
Why it matters
- Patients / advocates: ESCC patients progressing after first-line therapy need options that improve survival, not just response rates.
- Clinicians: The approval creates a new post-platinum, post-immunotherapy pathway in recurrent or metastatic ESCC.
- Regulators: China is approving novel ADC platforms in tumour types with major regional burden.
- Industry / innovation partners: Bispecific ADCs are moving from concept to approved oncology products, with global development implications.
The global oncology map is changing in real time.
China’s approval of iza-bren in recurrent or metastatic esophageal squamous cell carcinoma is not a small regional footnote. It is a sign that China-origin innovation is moving into serious, high-burden solid tumours with Phase III survival data behind it.
Iza-bren is a bispecific antibody-drug conjugate targeting EGFR and HER3. The NMPA approval covers adults with recurrent or metastatic ESCC whose disease has progressed after platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy. That is a population with few good options and poor outcomes.
The Phase III evidence matters. In PANKU-Esophagus01, iza-bren improved median overall survival from 7.2 monthswith chemotherapy to 9.8 months. Median progression-free survival doubled from 2.0 months to 4.2 months. The trial met both primary endpoints, and the study enrolled 497 patients across 80 centres in China.
For ESCC, that is a clinically meaningful move.
But the political story is larger than one product. For years, much of the world talked about innovation as though it moved in one direction: from U.S. and European R&D ecosystems outward. That picture is now outdated. China is building trial infrastructure, regulatory capacity and platform technologies that can generate globally relevant oncology evidence.
The access question remains. Approval in China does not automatically mean equitable access across provinces, hospitals or reimbursement channels. An ADC is not cheap to manufacture, purchase or deliver. It requires oncology capacity, toxicity monitoring and payer decisions that can turn a regulatory decision into real treatment availability.
There is also a global question. Iza-bren is being evaluated in other solid tumours, including lung, breast and urothelial cancers. If the platform continues to generate evidence, regulators and HTA bodies outside China will need to decide how they evaluate data generated through Chinese trials and how quickly they can move when the disease burden is global.
China has approved the drug. The next test is whether the system can deliver it, and whether the rest of the world is ready to engage with the evidence without old assumptions.
